Friday, July 31, 2015

Are You passionate about the Future of Biobanking? Join our event as a Guest Blogger!

Earn a complimentary all-access pass to the 8th Annual Biorepositories and Sample Management Summit by serving as a Guest Blogger at the event.



IIR's 8th Annual Biorepositories and Sample Management Summit
October 12- 14, 2015
Hilton Back Bay
Boston, MA

We are looking for an industry expert with interest in the following topics:

• New technology and innovative sample management;
• Sample Quality Assurance/Control Methods;
• Sustainable business models for Sample management
• Biospecimens;
Biobanking to Support Drug Development;
• Bioprocessing and Biopreservation Techniques;
• Precision medicine;

...and who would like to learn about the future trends in biobanking!

The premise is to provide Biorepositories and Sample Management - related articles, whitepapers, and overall original content.

What You get is:
• FREE pass to the conference (valued up to $2,195);
• Access to extensive social learning activities;
• Exclusive admission to a networking community in the industry of your interest!

You also have a chance to GAIN exposure through our five health related-blogs with over 2000 unique visitors monthly each and more than 20 healthcare LinkedIn groups. 

Learn more about the IIR's 8th Annual Biorepositories and Sample Management Summit by visiting the website.

Interested & want to learn more about this opportunity? Please contact Alexandra Pump at apump@iirusa.com

We hope to have you join us in Boston!

Stay tuned for our weekly news round up! 

Subscribe to our blog or follow us on Twitter: @futurebiopharma



Share this article with your social network, just click below to share now!


Wednesday, July 29, 2015

New Development in Monoclonal Antibodies!

A recent development in monoclonal antibodies for Alzheimer's was announced in an article by FierceBiotech Research. Scientists at NYU Langone Medical Center's Center for Cognitive Neurology is conducting a study that suggests monoclonal antibodies designed to specifically target misfolding proteins in soluble, aggregated states, could be ideally used to treat neurodegenerative diseases such as Alzheimer's, ALS, Parkinson's, and Huntington's.

Monoclonal antibodies are now used for treatments of a wide array of diseases, especially cancer, autoimmune, and inflammatory diseases and the studies are only expanding. With the market for monoclonal antibodies exploding to an estimated $31.7 billion by 2017, don’t miss out on the opportunity to discover the future of antibody engineering at the upcoming IBC’s Antibody Engineering & Therapeutics event.

This is the most trusted antibody engineering event in the industry where you will not only connect with over 700 antibody industry experts, but also learn about the latest antibody science and applications to expand your pipeline of antibody therapeutics.

Hear from the below experts this December 7-10  in San Diego, CA to uncover more about monoclonal antibodies and recent developments for non-cancer and orphan indications.

  • Trudi Veldman, Ph.D.., Senior Director Biologics Generation, AbbVie Bioresearch Center
  • Patrik Maurer, Ph.D., Head Research and Preclinical Development, ESBATech, a Novartis Company, Switzerland
  • Jos Raats, Ph.D., CEO, ModiQuest B.V., The Netherlands
  • Mary Keir, Ph.D., Scientist, Immunology, Tissue Growth and Repair (ITGR), Diagnostic Discovery, Genentech, Inc.
  • Ahuva Nissim, Ph.D., Reader in Antibody and Therapeutic Engineering, Biochemical Pharmacology, Queen Mary University, United Kingdom
  • Ulrich Wuellner, Ph.D., Associate Director, Discovery Research, Covagen AG, Switzerland
  • Chung-Ming Hsieh, D.SC., Associate Director, Biologics, AbbVie Bioresearch Center
  • James Larrick, M.D., Ph.D., Managing Director and Chief Medical Officer, Panorama Research Institute and Velocity Pharmaceutical Development
  • Bo Yu, Ph.D., Co-founder and CSO, Larix Bioscience, LLC
  • Wendy Williams Ph.D., Scientist II, Antibody Discovery and Protein Engineering, MedImmune, United Kingdom
  • Vaughn Smider, M.D., Ph.D., Assistant Professor, Department of Cell and Molecular Biology, The Scripps Research Institute
  • Mark De Boer, Ph.D., CEO, Fast Forward Pharmaceuticals BV, The Netherlands
  • Peter Ulrichts, Ph.D., Principal Scientist, arGEN-X BVBA, Belgium

Download the Brochure for the Full Session and Speaker Details.

Accelerate your antibody research, discovery efforts and clinical programs at the most comprehensive event for comparing and contrasting engineering, discovery and development strategies for different antibody modalities.

Plus, take advantage of an extra $100 off the current rate with code D15172BLOG - Register Now!



Share this article with your social network, just click below to share now!


Tuesday, July 28, 2015

Accelerate Your Cell, Gene and Cancer Immunotherapies to Market - Best Rate Ends Friday



Save $400 with the code XB15188BLOG by Friday, July 31 | Register here.

IBC's Cell Therapy Bioprocessing & Commercialization is the most focused conference for cost-effective and efficient cell, gene and immunotherapy approaches that accelerate cell-based product development and production towards commercial success >> Download the full agenda.

Key Topics Include: 
• Applying Genome Editing and Other Disruptive Technologies
• Developing Scalable and Transferrable Manufacturing Processes
• Biopreservation, Cold Chain Management and Patient Delivery
• Developing Successful Business Models
• Fostering Partnerships and Outsourcing Strategies for R&D and Manufacturing
• Pricing, Reimbursement, and Adoption
• Negotiating the Regulatory Pathways to Approval

_______________________________________________________________

Save $400 with the code IMMUNO15BL by Friday, July 31 | Register here.

IBC's Immuno-Oncology is the industry's leading resource for diving into the current issues surrounding efficacy and response rates with first generation immunotherapies to propel the next wave of cancer immunotherapies >> Download the full agenda.

Key Topics Include: 
• Strategies for Combination Therapeutics
• Advances with Checkpoint Inhibitors
• Agnostic Antibody Agents
• Advances in Cancer Vaccines
• Advancing the Next Wave of Cancer Immunotherapies


Share this article with your social network, just click below to share now!


Monday, July 27, 2015

How to successfully integrate continuous capture with perfusion bioreactors


In a previous post I described the drivers for, and, benefits from, the trend towards the continuousproduction of biopharmaceutical drugs in which I referenced the article of Veena Warikoo from Genzyme, a Sanofi company, and co-workers published in 2012 on the “Integrated Continuous Production of RecombinantTherapeutic Proteins” (Biotech Bioeng, 2012;109: 3018-3029). Amongst Veena’s contributing authors is Konstantin Konstantinov a key contributor to the literature on continuous bioprocessing and Keynote speaker at the Bioprocess International 2015 Conference with a presentation entitled “What is the Future of Continuous Processing  – What is the Time Frame for Implementing Fully Continuous Processing in Commercial Production?"
Extending continuous processing downstream to include the capture step

A key concept that the team from Genzyme developed is the integration of continuous chromatography with a perfusion bioreactor for the production of both high volume and stable monoclonal antibodies and low volume, less stable recombinant human enzymes. A 12 L bioreactor was operated for up to 70 days by utilizing the Alternating Tangential Flow (ATF) cell retention technology. The ATF permeate that was harvest was loaded directly onto a periodic counter current (PCC) chromatography system. Systems such as these are now available from a variety of suppliers including GE Healthcare, Pall, Semba and NovaSep. Genzyme were able to operate the PCC system in a fully closed and sterile state for a prolonged period of time.

The benefits of integrating continuous culture with continuous capture
Adopting this approach can lead to significant benefits because of the high cell densities and volumetric productivities that can be achieved. This allows significantly smaller bioreactors to be used thereby reducing facility size and capital costs. The ATF system eliminated the need for a more complex harvesting system, however, integration with PCC eliminated the need for large hold tanks, a non-value adding operation, and allowed the capture column to be reduced by a minimum of two-fold.

Improved product quality of less stable proteins

Integration of upstream and downstream operations in this way allows for the continuous flow of product from the bioreactor, through the capture step and into the chromatography eluate and mitigates the risk of product degradation of less stable proteins.

Though the issue of stability may be less of a concern for monoclonal antibodies, the team have created a platform capable of delivering a range of biopharmaceuticals from within a single facility.

What is the Time Frame for Implementing Fully Continuous Processing in Commercial Production?

How would you answer this question? Do you think the industry will see this within 5 years? 10 years? 20 years? Or more?

Dr Nick Hutchinson

Join me at #BPIconf

Dr Nick Hutchinson has a Masters and Doctorate in Biochemical Engineering from University College London, UK where he focused on laboratory tools for rapid bioprocess development and characterization. He then worked at Lonza Biologics in an R&D function investigating novel methods for large-scale antibody purification before moving to an operational role scaling-up and transferring manufacturing processes between Lonza sites in the UK, Spain and USA. Nick now works in Market Development at Parker domnick hunter where his focus is in bringing Parker's strengths in Motion & Control to Bioprocessing. This will enable customers to improve the quality and deliverability of existing and future biopharmaceuticals.


Share this article with your social network, just click below to share now!


What did last year's Antibody Engineering & Therapeutics attendees have to say about their experience?

See what attendees of last year's Antibody Engineering & Therapeutics had to say...

"Comprehensive coverage. In-depth analyses of the past, present and outlook of the antibody therapyfield/industry" - Li-Hsien Wang, Regeneron


"I am new in the antibody therapeutic field and this conference provides significant amounts of valuable information to me." - Ulrik Lademann, Senior Scientist, Symphogen

"This is best meeting dedicated to Antibodies! Small enough to be able to be able to interact with people and big enough to cover all the important topics" - Monica Schaller, University Hospital Bern Inselspit

"Great conference, inspiring atmosphere, very motivating speakers and encouraging networking sessions!! Would love to come back!" - Priyal Thakur, BD Biosciences

"Great conference! Informative and addresses state-of-the-art advances in antibody/drug technologies." - James Tamura, Macrogenics

"Beautiful overview on antibody modeling strategies of different players on the market!" - Tobias Raum, Amgen Research Munich

"The most updated conference on Antibody Engineering & Therapeutics" - Jean-Luc Teillaud, INSERM, France

"The workshop program continues to be a venue for in-depth exploration of specialty topics on antibodies" - Ray Sweet, Senior Director and Fellow, Biologics Research, Janssen R&D

"Informative and Timely!" - Colin Brenan, CTO, R&D, HiFiBio BV

"World class group of leading antibody researchers" - Caroll Osgood, Alleghany Brain and Spine


Don't miss out on the #1 forum for academia and industry to connect for scientific exchange and networking in antibody engineering & therapeutics, immunobiology and next-generation binders.

Check out the complete program here.

Register today with the code D15172BLOG and save $550!


Share this article with your social network, just click below to share now!


Thursday, July 23, 2015

Antibody Engineering & Therapeutics Interview | Paul Sondel, M.D. Ph.D., University of Wisconsin

The annual Antibody Engineering & Therapeutics is the #1 forum for academia and industry to connect for scientific exchange and networking in antibody engineering & therapeutics, immunobiology and next-generation binders. The 2015 event is taking place December 7-10 in San Diego, CA.

Below is an interview conducted at the 2014 event with Paul Sondel, M.D. Ph.D., Reed and Carolee Walker Professor of Pediatrics, Human Oncology, and Genetics, University of Wisconsin. At the event, Dr. Sondel presented "Translating Preclinical Immunocytokine Development into Clinical Testing"

Check out his interview below...



Want to hear more from experts like Dr. Sondel? Then join us at the 2015 Antibody Engineering & Therapeutics event. Register today at save $550 when you use the code D15172BLOG.

See you in San Diego!



Share this article with your social network, just click below to share now!


Wednesday, July 22, 2015

Today's Challenges in Cell Therapy


 

Joining us in this Cell Therapy Bioprocessing & Commercialization Podcast is Marty Giedlin, VP of Development at Sangamo BioSciences, Inc. Marty discusses key industry challenges, the evolution of the cell therapy field and where it is headed in the next five years, advancements in technology and much more. Below is a brief excerpt from the podcast, follow the links below to access the complete podcast and transcript.


What are the challenges that you’re experiencing in your industry?

Well, I guess it really depends on what kind of cell therapy you’re talking about. We at Sangamo are processing both autologous T-cells and autologous stem cells. We have the most experience in our T-cell program where we knock out the CCR-5 receptor for HIV in HIV-positive patients. So, the challenges are trying to find that patient population that’s most amenable to this type of therapy, both in viral load, how many years they’ve been in retroviral therapy and that sort of thing. And also finding out which of the CD4 cells – which sub-population – is most important in controlling HIV. So, those are some of the challenges that are facing us there.

With our stem cell program, we have a partnership with CIRM (California Institute for Regenerative Medicine) in California with the City of Hope where we are looking at using CD34 stem cells either from peripheral blood or from bone marrow. What sub-population of those cells are really those that have the capacity for self-renewal over time? Those are the cells that we really want to target to do our gene modification technology.

Then, there are culture conditions to minimize replication, retain stemness and maximizing engraftment with respect to CD34s. And then we’re looking at ways of mobilizing peripheral blood CD34s and how does that affect stemness with respect to CD34s? And then also looking at different ways of bone marrow harvest. So, are there better ways of getting maximal yield to make sure we get enough cells to give back to the patient?

So, for us in the adoptive cell therapy, those are some of the challenges that we’re looking at over the next three to five years.



Share this article with your social network, just click below to share now!


Tuesday, July 21, 2015

Single-Use Standardization on the agenda for BPSA at BPI Boston, 2015

“The BioProcess International Conference has always been a good venue for the Bio-Process Systems Alliance to work with industry to identify issues and define next steps”, say Todd Kapp, BPSA Board Member and Sales & Market Development Manager of Parker domnick hunter – North America.

The Bio-Process Systems Alliance is a leading trade association which facilitates the implementation of single-use bioprocessing through networking opportunities, creating a safe harbour for dialogue between industry and business leaders, providing forums for end-users and suppliers to work together and producing best practice guides.

“The BPSA has become a recognized leader in the industry for bringing users and suppliers of single-use technology together to discuss and educate one another on best practices and guidelines for implementation”, Kapp observes.

Single-Use Standardization

Along with other industry organizations such BPOG, PDA, ASTM and ASME BPE they will be participating in a Town Hall Forum Discussion on Single-Use Standardization at the BioProcess International Conference andExposition 2015 in Boston.

Standardization of single-use assemblies is an objective for many biomanufacturing organizations as they seek to reduce inventories and working capital. Historically, standardization exercises within the processing industries have been somewhat protracted affairs as various players try and agree on the preferred solution to standardize upon.

Todd Kapp (Parker domnick hunter & BPSA Board Member) 
EPICSolutions™ for Single-Use Technologies

Successfully implementing single-use technologies into biomanufacturing processes raises a number of issues that end-users are having wrestle with including the safety of the materials used, whether they shed particles or can maintain integrity and an increased reliance on the quality systems of their suppliers including their change notification procedures.

To help end-users address these issues the BPSA will be leading or contributing to sessions along the theme of EPICSolutions™ which stands for Extractables, Particles, Integrity, Change and Sustainability and was the main theme of the BPSA Summit held in Washington DC last week.

Kapp explains, “BPI has been and continues to be a great way for BPSA to communicate with the market and spread the word about the value it brings to industry”.

Without doubt BPI will be a richer learning experience for bioprocess engineers on their journey to implement single-use technologies by the inclusion of the BPSA in the program.

Dr Nick Hutchinson

Join me at #BPIconf
Dr Nick Hutchinson has a Masters and Doctorate in Biochemical Engineering from University College London, UK where he focused on laboratory tools for rapid bioprocess development and characterization. He then worked at Lonza Biologics in an R&D function investigating novel methods for large-scale antibody purification before moving to an operational role scaling-up and transferring manufacturing processes between Lonza sites in the UK, Spain and USA. Nick now works in Market Development at Parker domnick hunter where his focus is in bringing Parker's strengths in Motion & Control to Bioprocessing. This will enable customers to improve the quality and deliverability of existing and future biopharmaceuticals.


Share this article with your social network, just click below to share now!


Monday, July 20, 2015

Are you passionate about technical aspect of science around biotherapeutics? Join our event as a Guest Blogger!


Earn a complimentary all-access pass to Immunogenicity for Biotherapeutics (IFB) conference by serving as a Guest Blogger at the event.


IBC’s 16th Annual Immunogenicity for Biotherapeutics Conference
November 9-10, 2015
Hyatt Regency Reston
Reston, VA

We are looking for an industry expert with interest in the following topics:
• Immunology;
• Molecular biology;
• Bio-engineering;
• Microbiology;
• Molecular immunology, and more.

The premise is to provide Immunogenicity for Biotherapeutics - related articles, whitepapers, and overall original content.

What You get is:
• FREE pass to the conference (valued up to $2,399);
• Access to extensive social learning activities;
• Exclusive admission to a networking community in the industry of your interest!

You also have a chance to GAIN exposure through our five health related-blogs with over 2000 unique visitors monthly each and more than 20 healthcare LinkedIn groups.

Learn more about the IBC's Immunogenicity for Biotherapeutics event by visiting the website

Interested & want to learn more about this opportunity? Please contact Krista Lentini at klentini@iirusa.com or directly at 646-895-7316.

We hope to have you join us in Reston!

Cheers, The IBC's Immunogenicity for Biotherapeutics Team 2015
@ibcusa
#ibcImmuno
http://www.ibclifesciences.com/Immunogenicity/overview.xml
Future of Biopharma Blog http://futurebiopharma.blogspot.com/


Share this article with your social network, just click below to share now!


Wednesday, July 15, 2015

Unlock the Key to Advancing Immuno-Oncology

As innovations and discoveries in cancer immunotherapies progress at lightning speed, it is critical to understand the successes and challenges with current immunotherapies to separate the hype from the real opportunities. IBC's Immuno-Oncology event develops tactics for improving the efficacy and response rates with first generation immunotherapies and builds a strategy for utilizing combination therapies, t-cell therapies, and checkpoint inhibitors to propel the next wave of cancer immunotherapies.

Download the Immuno-Oncology brochure now to create your pathway for an answer to cancer: http://bit.ly/1O6tbIZ

Immuno-Oncology
Advancing the Next Generation of Cancer Immunotherapies
September 30 – October 1, 2015
Hilton Alexandria Mark Center, Alexandria, VA

Register today and explore the latest advances in Immuno-Oncology to:

Develop next generation immunotherapies by understanding recent advances made with CAR-T and T-Cell therapies, checkpoint inhibitors, cancer vaccines, and agnostic antibodies
Create a successful combination therapy strategy by gaining insights from global leaders on effective combinations
Optimize the discovery and development of your promising immunotherapies by hearing best practices and lessons learned from the first wave of cancer immunotherapies

Download the brochure for full program details: http://bit.ly/1O6tbIZ

Reserve your seat now. Use code IMMUNO15BL to get $100 off the current rate. Register today: http://bit.ly/1O6tbIZ

Best,
The Immuno-Oncology Team 2015
@ibcusa

#Immuno15


Share this article with your social network, just click below to share now!


Highlights from the 2014 Antibody Engineering & Therapeutics Conference


The annual Antibody Engineering & Therapeutics is the #1 forum for academia and industry to connect for scientific exchange and networking in antibody engineering & therapeutics, immunobiology and next-generation binders.  The 2015 event is taking place December 7-10 in San Diego, CA. Below are highlights from the 2014 event...




Interested in attending the 2015 event? Register today and save $550 when you use the code D15172BLOG


Share this article with your social network, just click below to share now!


Tuesday, July 14, 2015

How will cell therapy change in the next five years?


Joining us in this Cell Therapy Bioprocessing & Commercialization Podcast is Anthony Davies, President of Dark Horse Consulting. Anthony discusses key industry challenges he is seeing, the evolution of the field in the next five years, some exciting new initiatives he is working on, regulatory issues and much more. Below is a brief excerpt from the podcast, be sure to click on the links below to access the complete podcast.


How do you see the field of cell therapy changing in the next five years? 

I believe strongly that the next five years will bring the first significant drug approval. This will be a transformative moment for the field. A lot of players who are sitting on the wings will move in and there will be a big acceleration. Who will benefit from that the most are the organizations and the entities which have spent the difficult, recent years preparing and positioning themselves the best. 

I think we would do well to look around at this point because it will – in a sense – be the calm before the storm. The companies which are working fervently now preparing themselves to be able to take their drugs all the way to commercialization are the ones who are going to step in to the fast lane when the first big approval comes. And as I said, I do think that the next five years is a very realistic timeframe for this to occur.

[The above was a brief excerpt from the podcast]


Share this article with your social network, just click below to share now!


Monday, July 13, 2015

QbD for Cell Culture: Four steps for creating a 'design-space'



Quality by Design (QbD) is an approach to developing control strategies for biopharmaceutical manufacturing strategies that seeks to instil quality into the production process rather than relying on the testing of product quality once produced. The QbD paradigm for biomanufacturing has its origins in the FDA’s ‘cGMP initiative for the 21st century’ from 2004.

Three key components of QbD for Biologics
Three key components of the QbD approach have been previously defined as:
1.    Process knowledge with an understanding of inputs and their impact on process performance.
2.    Understanding the relationship between the process and the product’s critical quality attributes (CQAs)
3.    Understanding the connection between CQAs and a products clinical properties (Rathore & Winkle, 2009, Nat Biotechnology 27(1) 26-34)
Tom Hayes from Genzyme will be presenting on the ‘Application of Quality by Design principles to the development, characterization and scale-up of a late stage perfusion cell culture process” at BPI Boston, 2015 as part of the Process Characterization, QbD and Technology Transfer session.

A four step approach to defining a design-space for cell culture
Shukla and the team developed process understanding in which the effect of varying input variable on CQAs was understood for a non-continuous cell culture step with the following approach:
1.    Use of failure modes effects analysis (FMEA) to identify and allocate a risk priority number to process parameters and that could influence cell culture performance.
2.    Qualification of a 7L scale-down production bioreactor model.
3.    Two stage design of experiments methodology (2-level Resolution IV and face-centered central composite designs) with the scale-down model to map the design space.
4.    Performance of linking studies to show the effect of upstream conditions on process- and product-related impurity clearance by downstream purification steps.

The link between cell culture process parameters and CQAs
The group found that production bioreactor pH, temperature and initial viable cell density impacted product glycosylation and basic banding on isoelectric-focussing gels. Bioreactor temperature also affected product deamination. Host cell protein levels in Protein A eluates was shown to be impacted by the cell viability at harvest.
Have your say
To what extent to you think the industries approach to QbD for cell culture steps has developed since the Shukla paper from 2010? How applicable is a study such as this, based on non-continuous culture, be too continuous cell culture?

 

Dr Nick Hutchinson
Join me at #BPIconf

Dr Nick Hutchinson has a Masters and Doctorate in Biochemical Engineering from University College London, UK where he focused on laboratory tools for rapid bioprocess development and characterization. He then worked at Lonza Biologics in an R&D function investigating novel methods for large-scale antibody purification before moving to an operational role scaling-up and transferring manufacturing processes between Lonza sites in the UK, Spain and USA. Nick now works in Market Development at Parker domnick hunter where his focus is in bringing Parker's strengths in Motion & Control to Bioprocessing. This will enable customers to improve the quality and deliverability of existing and future biopharmaceuticals.



Share this article with your social network, just click below to share now!


Friday, July 10, 2015

This Week in BioPharma: 7/5-7/10 - $80 million dollars in pharma packaging and more

Healthcare med device makers ensure more guarantees
Med device manufacturers are being pushed toward taking partial responsibilities for faulty products alongside with insurers and U.S. hospitals. In the competitive environment, often pressed by insufficient demand, suppliers slowly move toward taking a risk and providing additional guaranties to gain an edge on the marketplace. Reuters, UK reports that in recent years there were billions of dollars paid to settle court claims of unsatisfied and at times unable to covers additional costs of treatment customers. The emerging trend is pushing medical device makers to not just cover the cost of broken or defective parts but to become accountable for health outcomes.

Vaccine products are said to reach $40 billion in sales by 2020. According to a recent report by the Tufts Center for the Study of Drug Development this number has tripled comparing to 2005. Research and development of vaccine products are on the rise. It is explained by many factors include the healthcare system and reluctance of healthcare providers to deliver long-term care for patients as well as continuous advances in cancer treatment research. The "Vaccine products in the R&D pipeline have more than tripled since 2005" report also suggests that while vaccine product makers are in the development phase at full speed, one of the obstacles they may face is distrust that consumers express toward vaccination as a general trend.

The packaging market in pharmaceutical industry in projected to reach $80 million dollars in value by 2020. Packaging of pharma products aims to protect the products from external influence, extend it shelf-life as well as cover all legal aspects. The pharmaceutical packaging market is rapidly growing due to steady progress in drug and vaccine development, and therefore the need of appropriate up-to-date packaging that responds to ever-changing demands of capricious consumers persists.

Biotech industry on the East Coast is represented by HocusLocusNot true they say, that biotech industry belongs to the West Coast - a biotech company from NY (Albany) was awarded more than $1 million in grants from the National Institutes of Health and the National Science Foundation. HocusLocus is focusing its attention on developing a cure against HIV and Ebola through the "switchable" mechanism that allows to switch from one gene to another one potentially killing cancer cells and viruses.


About the author: Ksenia Newton, a Digital Marketing Assistant at IIR USA, Pharma Division, who works on various aspects of the industry including social media, marketing analysis and media. She can be reached at knewton@iirusa.com


Share this article with your social network, just click below to share now!


Thursday, July 9, 2015

The Antibody Engineering & Therapeutics Final Agenda is Now Available












The Antibody Engineering & Therapeutics Final Agenda is Now Available! Click Here to Download Your Copy >>

At the upcoming IBC's 26th Annual Antibody Engineering & Therapeutics meeting in San Diego, CA on December 7-10, 2015, connect with 700+ of your peers and industry experts to discover, engineer and develop novel and next-generation antibody modalities across diverse disease indications.

This year's program includes an impressive collection of world-renowned and highly-published academic and industry scientists, who will be sharing the latest science, strategies and preclinical/clinical development efforts.

Download the brochure today to see how you can fast-tract your antibody research to the clinic and beyond at the most trusted antibody engineering and therapeutics event of the year!

Learn About The Latest Antibody Science and Applications:
• 64 unpublished and new data presentations from trusted industry and academic scientists
• 100+ research projects presented live in the Poster Hall with one-on-one access to the researchers
• 16+ Scientific Briefings to help you apply novel technologies

Expand Your Pipeline of Antibody Therapeutics: 
• Find and exploit new antibody targets beyond the “low-hanging fruit”
• Overcome the challenges of complex molecules like bispecifics, fusions, ADCs, antibody combinations to gain a competitive advantage
• Assess lessons learned from numerous preclinical and clinical projects to accelerate your molecules

PLUS! We're excited to announce the ALL-NEW Antibody-Drug Conjugate (ADC) Development track, covering: 
• Novel conjugation approaches
• Novel linkers and payloads
• Preclinical and clinical results
• New ADC targets • Strategies to maximize potency
• Widening therapeutic window
• Improving process development and analytics for ADCs

Register today to take advantage of the early-bird savings of up to $450 – Plus take an EXTRA $100 off with the code D15172BLOG | Click here to register.


Share this article with your social network, just click below to share now!


Wednesday, July 8, 2015

The Greatest Challenges in Cell Therapy Today


Joining us in this Cell Therapy Bioprocessing & Commercialization Podcast is Jeff Karp - Associate Professor of Medicine at Brigham and Women's Hospital, Harvard Medical School. Jeff talks about the challenges facing the cell therapy space, how to improve cell homing following transplantation, and control cells among other things.


What are some of the greatest challenges in cell therapy today? 

I think that we’re getting to a point in time where we can obtain almost any cell type in unlimited quantities with a few exceptions. This is using reprogramming, programming, different differentiation, protocols that have recently been worked out. So, I really think we are getting to that point where we can obtain nearly any cell type that can then be delivered to patients for treatment. 

While I think we’re there, I think one of the greatest challenges that remains is that once we transplant cells, we lose control over the cells. So, when we’re working with cells in a Petri dish, for example, we can pattern the media, we can put cells on all different types of textured substrates, we can control the media and the environment exquisitely. But, when we transplant cells, they are entirely at the mercy of the biological. So, if they end up in different tissues in the body, they are going to behave completely differently. So, we lose control of those cells following transplantation.

So, I think one of the greatest challenges is how can we now take the cells that we worked so hard to derive in vitro and then transplant those cells into patients and exhibit control so that the cells get to the right location and can perform their function when they get there.

[The above was an excerpt from the podcast]


Share this article with your social network, just click below to share now!